By Jordan of http://investmentunderground.com/
We ran a screen to filter picks that Warren Buffett would like: sustainable business advantages producing significant free cash flows, and healthy returns on equity in excess of 10%.
We also screened for market caps larger than $10 billion in order to “move the needle,” meaning, Warren could acquire enough shares to make the investment worthwhile given Berkshire’s size.
Q2 Hedge Funds Resource Page Now LIVE!!! Lives, Conferences, Slides And More [UPDATED 7/12]
Simply click the menu below to perform sorting functions. This page was just created on 7/1/2020 we will be updating it on a very frequent basis over the next three months (usually at LEAST daily), please come back or bookmark the page. As always we REALLY really appreciate legal letters and tips on hedge funds Read More
We provide 12 names that are consistent with Berkshire’s investment philosophy. One is a current holding (BDX) and one is a former holding (WU). Of the 12 picks, 8 are healthcare related. Considering Buffett’s ever-increasing stake in Johnson and Johnson (JNJ), any of the names in this screen are fair game for an entry by the conglomerate.
Abbott Laboratories (ABT): This pharmaceutical powerhouse yields 3.61% and has a history of raising its dividend. The company’s portfolio of patent protected drugs, along its excellent nutritional and diagnostic groups and its history of strategic acquisitions have dug ABT a wide economic moat, a criterion Buffett demands for many of his investments.
Becton, Dickinson & Company (BDX): Another healthcare giant, Becton has carved out significant market share in the medical tool market. As of 9/30/2010, Buffett owns .81% of shares outstanding. And like Abbott, Becton has a long history of raising its dividend, which is among the highest in the industry (1.9%). But unlike ABT, Becton doesn’t have a sea of patent protected drugs to shield it from competition and many of its products have been commoditized, creating a narrow moat for the company.
Cisco Systems (CSCO): Buffett has brought tech executives to Berkshire’s board, including Susan Decker. As well, Bill Gates, Walter Scott, Jr. and lawyer Ronald Olsen are not strangers to old and new technologies. Cisco is the dominant player in data networking produces tons of cash-flow and will continue to as this growth story keeps growing.
Covidien (COV): This producer of all things healthcare is raising its quarterly dividend 11% to $.20 a share. This is the second consecutive year COV has upped its yield.
Exelon (EXC): With the largest nuclear fleet of any U.S. utility, Exelon’s 11 nuclear plants generate 17% of U.S. nuclear power and constitute 80% of Exelon’s generation output. This is a low risk, wide moat operation with room to run. The company has traded upwards of $85 a piece. At the time of writing, EXC trades at $40 a share and yields 5.3%.
France Telecom (FTE): FT spits off about 8 billion euros a year in free cash flow and should continue to for the next 5 years, allowing the company to pay off its debt load of around 34 billion errors net of cash and continue to increase its dividend which yields 5.7%. FTE as well has a solid history of increasing its dividend, though it did cut it in half during 2009 due to slowed wireless and broadband growth.
Medtronic (MDT): This company dominates the medical equipment space, holding market leading positions in heart devices, insulin pumps, and spinal products. Medtronics trades on a TTM price to earnings ratio of 10.9. Compare that to an industry P/E of 16.5, throw in a 2.5% yield, a wide economic moat, and a recent increase in Goldman’s price target to $36 a share, and you have a stock that fits Berkshire’s investment philosophy.
Novartis (NVS) The Swiss-based pharmaceutical maker has a healthy balance sheet and a free cash flow yield of ~ 8%. The company’s healthy intellectual property portfolio has created a wide moat for itself, which will likely remain as long as Novartis can continue to fuel its late stage pipeline and keep making targeted acquisitions.
Roche Holdings (RHHBY) The other big boy of the Swiss pharma giants, Roche yields 3.2% and has a solid drug portfolio and pipeline, due to the company’s acquisition of Genentech in 2009.
St. Jude Medical (STJ): One of Medtronic’s biggest rivals, St. Jude’s maintains an economic moat thanks to its diversified product offering and its key position in the $550 million dollar vascular closure market. What’s more, 45% of STJ’s sales come from abroad. The company could easily trade in the $45-$50 per share range as healthcare spending recovers along with the broader economy.
Western Union (WU): Buffett has owned WU in the past. And for good reason. The company is the largest money transfer company in the world. The size of the company has proved to be an advantage as many smaller rivals have been driven out of business because of regulatory requirements they couldn’t keep pace with.
Zimmer Holdings (ZMH): Shares of ZMH appear cheap considering the company’s market share and demographic trends on the horizon. The company leads the hip and knee implant industry, an industry which should see solid growth as the baby boomers keep getting older.
Disclosure: The author of this article may have holdings in the companies above. This is neither a buy nor sell recommendation. Every investor must do their own due diligence.